AI assistant
GlaxoSmithKline PLC — Director's Dealing 2016
Sep 19, 2016
5262_dirs_2016-09-19_7fb69747-6e1a-4f42-8afa-a3359bb994c4.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 2357K
GlaxoSmithKline PLC
19 September 2016
GlaxoSmithKline plc (the 'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr K Slaoui
b)
Position/status
PCA of Dr M M Slaoui (Chairman, Global Vaccines)
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
GlaxoSmithKline plc American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Nature of the transaction
An increase of 1 ADS following the notional allocation of ADSs on 15 September 2016, at a price of $43.54 per ADS, as a result of the revaluation of the cash element of the notional investment held within the GSK 401(K) plan.
c)
Price(s) and
volume(s)
| Price(s) | Volume(s) |
| $43.54 | 1 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2016-09-15
f)
Place of the transaction
n/a
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHZKLFFQKFFBBF
//<![CDATA[$.ajaxSetup({headers: {'__RequestVerificationToken':'GCvR0fJlZ6wtmD7zn1prqbwNLbFscA7xANNiUJfweIwrd3Gh5iAgjT0G1Jly87fP9qwxVA4tHL-8Jbq3bMIlgPY0Y4GzKorpYfW3p6dvcLY1:sheqoFPDn93ez4sy_x0p7hebX2F0ID9EOabkPxoeldM_CoYiNbe_DLgyHFU3HwwxpI9r0QzewFhzlJzUhdjgnHRiw9tKqLpqZG_qVwRKOyI1'}});//]]>